ICCC MEXC RealStocks
Own real ICCC shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:55:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Immucell Corp. (ICCC) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $11.22, with a market capitalization of $103.01M and a P/E ratio of 54.80. Over the past 52 weeks, its price has ranged from $4.52 to $12.10. This page covers its latest market performance, valuation, price trends and company information.
$103.01M | |
$11.31 | |
$11.46 | |
$10.50 | |
$11.33 | |
10.27K | |
13.35K | |
54.80 | |
$12.10 | |
$4.52 | |
-- | |
2026-09-30 |
Immucell Corp. (ICCC) last closed at $11.22 as of 2026-11-18 21:11:00, down 0.49% ($0.05) from the previous close of $11.33.
During the latest regular trading session, ICCC traded between $10.50 and $11.46, with a volume of 10.27K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Immucell Corp. (ICCC) moved from $10.26 to $11.22, representing a gain of 9.36% ($0.96).
The stock traded between $10.00 and $11.73 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 28.18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 88.4%
ICCC is currently trading at $11.22, placing it 88.4% of the way from its 52-week low of $4.52 to its 52-week high of $12.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immucell Corp. (ICCC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ICCC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ICCC shares and USD.
ICCC Shares to USD
1.00 ICCC shares = 11.22 USD
Calculations are estimates based on the latest available price and are for reference only.